AmeriWater Acquires Med Water to Expand Clinical Solutions
DAYTON, Ohio, July 17, 2026 AmeriWater, a leading provider of water purification systems for critical healthcare applications, has announced...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
DAYTON, Ohio, July 17, 2026 AmeriWater, a leading provider of water purification systems for critical healthcare applications, has announced...
SINGAPORE, July 14, 2026 The National University Hospital (NUH) has announced plans to significantly expand its use of wearable...
BIRMINGHAM, United Kingdom, July 7, 2026 Healome Therapeutics, a University of Birmingham spinout developing an innovative eye-drop matrix technology...
NEW YORK, July 7, 2026 Regal Healthcare Capital Partners has successfully completed the final close of Fund IV, securing...
BRUSSELS, June 23, 2026 Cognivia announced a strategic collaboration with Mayo Clinic to advance the use of behavioral intelligence...
TELFORD, Pennsylvania, June 22, 2026 Draeger, Inc., the U.S. headquarters of global medical technology leader Dräger, has announced that...
NORTH CHICAGO, Illinois, and SAN FRANCISCO, California, June 22, 2026 AbbVie has announced a definitive agreement to acquire Apogee...
SYDNEY, Australia and AUCKLAND, New Zealand, June 21, 2026 Murj®, a leading provider of cardiac device management software, has...
ZUG, Switzerland, June 21, 2026 MoonLake Immunotherapeutics has announced compelling Week 52 results from its Phase 3 VELA clinical...
BOSTON, June 22, 2026 Mighty Therapeutics, formerly known as Stealth BioTherapeutics, has officially announced its corporate rebranding, marking a...
